UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

Published
  • RISE data show UZEDY to be an effective long-acting injectable (LAI) antipsychotic treatment option for adults with schizophrenia, with a known safety profile consistent with other formulations of risperidone1
  • In the RISE study, UZEDY significantly prolonged time to impending relapse by up to 5.0 times (once-monthly dosing) versus placebo in patients with schizophrenia1
  • The U.S. Food and Drug Administration (FDA) approved UZEDY in April 2023 for the treatment of schizophrenia in adults as a subcutaneous injection dosed every one or two months

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy and safety findings from the phase 3 Risperidone Subcutaneous Extended-Release (RISE) study in The Lancet Psychiatry. The data supported the FDA approval for UZEDY, which was approved in April 2023 for the treatment of schizophrenia in adults as a subcutaneous injection every one or two months using a pre-filled syringe.

In RISE, UZEDY significantly prolonged time to impending relapse by 5.0 times with once-monthly dosing (HR 0.200, 95% CI 0.109–0.367; log rank p

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

TEVA